

Date and Time: *Wednesday 24th October 2012 (10.00-16.00)*

Minutes: Final

Guideline Development Group Meeting 3

Place: *Boardroom, National Clinical Guideline Centre (NCGC), 180 Great Portland Street, London W1W 5QZ*

Attendees:

Campbell Cowan (Chair)	(CC)	
John Campbell	(JC)	
Matthew Fay	(MF)	Present for notes 1-7
David Fitzmaurice	(DF)	Present for notes 1-7
Steven Hunter	(SH)	
Clifford Mann	(CM)	
Nick Mills	(NM)	
Eileen Porter	(EP)	
Suzannah Power	(SP)	
Rebekah Schiff	(RSf)	Present for notes 5-9
Richard Schilling	(RS)	
Joanna Ashe	(JA)	Present for notes 3 and 7
Liz Avital	(LA)	
Kathy De Mott	(KDM)	
Clare Jones	(CJ)	
Zahra Naqvi	(ZN)	
Vicki Pollit	(VP)	
Sharon Swain	(SS)	

Apologies:

V-Lin Cheong	(VC)
George Chung	(GC)
Gregory Lip	(GL)
Clifford Middleton	(CMn)

Observers: None

Notes

1. **Welcome and apologies for absence**

CC welcomed the group to the third meeting of this GDG. Apologies were received from V-Lin Cheong (VC), George Chung (GC), Gregory Lip (GL) and Clifford Middleton (CMn). CC welcomed Steven Hunter (SH) who was attending this GDG meeting as a co-opt expert on the surgical ablation evidence. The GDG accepted the minutes as an accurate record of the previous meeting.

Notes

The Chair asked all GDG members to declare any changes to their declarations of interest.

MF: Personal pecuniary interest; was taken for a meal with Sanofi-Aventis. Non-personal pecuniary interest; series of workshops on 'stop/start campaign' which is part of stroke prevention in atrial fibrillation (SPAF) Academy, funded through Boehringer Ingelheim. Personal pecuniary interest; involvement with the development of a national patient decision aid. I continue to work with the AF association for which I am not paid.

RS: Personal pecuniary interest; Travel and accommodation to teach at EP course from European Society of Cardiology. Personal non-pecuniary interest; filmed video for patient information for atrial fibrillation ablation for Hansen medical.

DF: Personal pecuniary interest; Attendance at ESC – 25-28 August that was funded by Boehringer Ingelheim. Presentation at symposium on 15th September 2012 that was funded by Bayer. Attendance at SAPC/RCOP meeting at Glasgow on 2-5 October 2012. Attendance at Garfield TSC – London on 11-12 October. Attendance at NIHR-HTA Commissioning board– London 16-17 October.

SH: Personal pecuniary interest; I provide consultancy work to Atricure and I am a proctor for their training programme. Atricure make ablation devices for the treatment of atrial fibrillation and a device for closing the left atrial appendage. I provide educational/consultancy (proctoring) to St Jude Medical and Edwards Lifesciences. Personal non-pecuniary interest; I have a clinical interest in the surgical treatment of atrial fibrillation and consequently I have an international reputation. I am frequently invited to international meetings to talk on the subject.

CJ: Personal non-pecuniary interest; attendance at the Cardiology update on 10 October 2012 in London.

LA: Personal non-pecuniary interest; attendance at the Cardiology update on 10 October 2012 in London.

The remaining GDG members and NCGC technical team declared no changes. No actions were taken following the declarations and none of the GDG members withdrew during discussion.

Notes

2. **Clinical and cost effectiveness on catheter ablation**
SS and VP presented the clinical and cost effectiveness evidence on catheter ablation.
3. **Clinical and cost effectiveness protocols session**
The GDG discussed the content of protocols for future clinical evidence reviews.
4. **Clinical and cost effectiveness on surgical ablation**
SH gave an introductory presentation into surgical ablation.
KDM and VP presented the clinical and cost effectiveness evidence on surgical ablation.
5. **Clinical and cost effectiveness on surgical ablation versus catheter ablation**
CJ and VP presented the clinical and cost effectiveness evidence on surgical ablation compared to catheter ablation.
6. **Economic Plan**
The GDG discussed the economic plan for the guideline.
7. **Clinical and cost effectiveness protocols session continued**
The GDG discussed the content of protocols for future clinical evidence reviews.
8. **Summary of the next steps and any other business**
CJ confirmed that the GDG meeting on 8th January 2013 had been cancelled and that there was a new meeting planned for Tuesday 10th September 2013. There was no other business.
9. **Close of meeting**

Date, time and venue of next meeting

Wednesday 5th December 2012, 10.00-16.00 Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.